UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action

Annals of oncology, 2020-10, Vol.31 (10), p.1289-1290

2020

Volltextzugriff (PDF)

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

ESMO open, 2022-04, Vol.7 (2), p.100399, Article 100399

2022

Volltextzugriff (PDF)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

British journal of cancer, 2013-08, Vol.109 (3), p.552-558

2013

Volltextzugriff (PDF)

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

Annals of oncology, 2013-02, Vol.24 (2), p.454-462

2013

Volltextzugriff (PDF)

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

Annals of oncology, 2012-12, Vol.23 (12), p.3116-3122

2012

Volltextzugriff (PDF)

MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises

Current pharmaceutical design, 2014-01, Vol.20 (24), p.3982-3990

2014

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

Annals of oncology, 2017-10, Vol.28 (10), p.2547-2551

2017

Volltextzugriff (PDF)

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

Lung cancer (Amsterdam, Netherlands), 2011-03, Vol.71 (3), p.249-257

2011

Volltextzugriff (PDF)

Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma

Heliyon, 2024-08, Vol.10 (16), p.e36306, Article e36306

2024

Volltextzugriff (PDF)

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey

Supportive care in cancer, 2018-06, Vol.26 (6), p.1841-1849

2018

Volltextzugriff (PDF)

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

ESMO open, 2022-12, Vol.7 (6), p.100644, Article 100644

2022

Volltextzugriff (PDF)

183P Second-line treatment selection in patients with non-small cell lung cancer of adenocarcinoma histology: A European survey

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S137-S137

2016

Volltextzugriff (PDF)

Targeted therapies and immunotherapy in non-small-cell lung cancer

Ecancermedicalscience, 2016-06, Vol.10, p.648-648

2016

Volltextzugriff (PDF)

Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience

Annals of oncology, 2018-10, Vol.29, p.viii533-viii533

2018

Volltextzugriff (PDF)

Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study

European journal of neurology, 2013-05, Vol.20 (5), p.788-794

2013

Volltextzugriff (PDF)

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

Clinical & translational oncology, 2020-06, Vol.22 (6), p.844-851

2020

Volltextzugriff (PDF)

The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey

Annals of oncology, 2017-10, Vol.28, p.vi58-vi58

2017

Volltextzugriff (PDF)

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

Lung cancer (Amsterdam, Netherlands), 2011-04, Vol.72 (1), p.3-8

2011

Volltextzugriff (PDF)

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database

ESMO open, 2024-09, Vol.9 (9), p.103680, Article 103680

2024

Volltextzugriff (PDF)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

British journal of cancer, 2008-07, Vol.99 (1), p.51-56

2008

Volltextzugriff (PDF)

Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial

Annals of oncology, 2017-10, Vol.28, p.vi54-vi54

2017

Volltextzugriff (PDF)

Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies

Annals of oncology, 2017-10, Vol.28, p.vi2-vi2

2017

Volltextzugriff (PDF)

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

International Journal of Breast Cancer, 2014-01, Vol.2014 (2014), p.1-7

2014

Volltextzugriff (PDF)

Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective

Annals of oncology, 2013-05, Vol.24 (5), p.1418-1419

2013

Volltextzugriff (PDF)

1 – 25 von 234

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(214)
Mit Volltextzugriff
(212)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

183P Second-line treatment selection in patients with non-small cell lung cancer of adenocarcinoma histology: A European survey

Targeted therapies and immunotherapy in non-small-cell lung cancer

Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience

Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial

Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

Suchergebnisse filtern